Lea Eslava-Kim, PharmD

Alinity i TBI lab test measures complementary biomarkers in blood plasma and serum that are tightly correlated to brain injury when elevated.

The phase 3 ELEVATE 12 trial evaluated the efficacy and safety of etrasimod 2mg once daily vs placebo in 354 patients.

DERBY and OAKS are phase 3, multicenter, randomized, double-masked, sham-controlled studies.

The Cionic Neural Sleeve is the first product to combine movement analysis and augmentation into a wearable garment.

Investigators conducted a noninterventional, multicenter study (APOLON) in patients receiving frontline pazopanib therapy.

Patients with IBD were compared to control groups without IBD, which included 14 completely vaccinated healthcare workers and 29 vaccinated healthy volunteers.

Previous studies have shown that GLP-1RAs demonstrate a protective effect by attenuating bronchial hyperresponsiveness.

Both doses of baricitinib met the primary end point, demonstrating statistically significant improvement in scalp hair regrowth compared with placebo.

Of the 139 athletes who wore the Q-Collar, 77% showed no significant changes in the deeper tissues of the brain involved in the transmission of electrical nerve signals.

Treatment with casimersen led to a statistically significant increase in dystrophin production in skeletal muscle from baseline to week 48.